What does Kaiser Permanente Southern California require to renew Wegovy?

Heart Disease Risk Reduction — Applies to Employer plans. Renewal requires: (1) confirmed cardiovascular disease (prior MI, prior stroke, carotid artery stenosis ≥50%, or symptomatic PAD); (2) continued use with reduced calorie diet and increased physical activity; (3) no concurrent GLP-1 or GLP-1/GIP agonist; (4) continued history of use or contraindication to GDMT (antiplatelet, statin, blood pressure medication). BMI threshold and age are NOT re-verified at renewal.

How current is this information?

The oldest review date among the policies on this page is June 5, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Kaiser Permanente Southern California coverage for

Does Kaiser Permanente Southern California cover Wegovy for Heart Disease Risk Reduction?

Yes. Kaiser Permanente Southern California covers Wegovy for heart disease risk reduction with prior authorization if your BMI is 27 or higher. Other policy requirements and your plan's benefits also apply.

Policy document

Standard Commercial Guidelines 6 1 26 Excerpted

Kaiser Permanente Southern California · PA policy · Employer

Effective June 1, 2026. Verified June 5, 2026.

View PDF Download Original insurer source

Employer: Covered with requirements. See the qualification pathways below.

Earliest policy review June 5, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Heart Disease Risk Reduction (1 plan type)

Applies to Employer plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction — Initial Approval

All of:

Age ≥ 18 years
BMI ≥ 27 kg/m² (or ≥ 25 kg/m² if Asian)
Established cardiovascular disease (prior MI, prior stroke [ischemic or hemorrhagic], carotid artery stenosis ≥50%, or symptomatic PAD with ABI <0.85, peripheral arterial revascularization, or amputation due to atherosclerotic disease)
History of and continued use of, or contraindication to, ALL GDMT: antiplatelet agent (unless history of hemorrhagic stroke), statin, and blood pressure medication (ACEi, ARB, or beta blocker)
Used in combination with reduced calorie diet and increased physical activity
No concurrent use of another GLP-1 receptor agonist or GLP-1/GIP receptor agonist

Documentation to bring

Documentation of age ≥ 18 years
Baseline BMI documentation (≥ 27 kg/m² general, or ≥ 25 kg/m² for Asian patients)
Documentation of qualifying established CVD event (prior MI, prior stroke, carotid artery stenosis ≥50%, or symptomatic PAD with ABI <0.85 at rest, peripheral arterial revascularization, or amputation due to atherosclerotic disease)
Documentation of current GDMT use or clinical reason GDMT is contraindicated: antiplatelet agent, statin, and blood pressure medication (ACEi, ARB, or beta blocker)
Documentation that Wegovy will be used with reduced calorie diet and increased physical activity
Confirmation of no concurrent GLP-1 receptor agonist or GLP-1/GIP receptor agonist use

Approval and renewal

Renewal: Renewal requires: (1) confirmed cardiovascular disease (prior MI, prior stroke, carotid artery stenosis ≥50%, or symptomatic PAD); (2) continued use with reduced calorie diet and increased physical activity; (3) no concurrent GLP-1 or GLP-1/GIP agonist; (4) continued history of use or contraindication to GDMT (antiplatelet, statin, blood pressure medication). BMI threshold and age are NOT re-verified at renewal.

Not covered when

Concurrent use of another GLP-1 receptor agonist (liraglutide, exenatide, semaglutide other products) or GLP-1/GIP receptor agonist (tirzepatide products)

Policy note: GDMT antiplatelet requirement has an exception: if the patient has a history of hemorrhagic stroke, antiplatelet is not required. At renewal, the BMI threshold is not re-verified — only CV disease confirmation, GDMT, diet/activity, and no concurrent GLP-1 are checked.

Policy effective June 1, 2026 · verified June 5, 2026 · source: Standard Commercial Guidelines 6 1 26 Excerpted · View policy document (PDF)

Open on its own page →

Questions people ask

Does Kaiser Permanente Southern California cover Wegovy?: Yes. Kaiser Permanente Southern California covers Wegovy for heart disease risk reduction with prior authorization if your BMI is 27 or higher. Other policy requirements and your plan's benefits also apply.
What does Kaiser Permanente Southern California require to renew Wegovy?: Heart Disease Risk Reduction — Applies to Employer plans. Renewal requires: (1) confirmed cardiovascular disease (prior MI, prior stroke, carotid artery stenosis ≥50%, or symptomatic PAD); (2) continued use with reduced calorie diet and increased physical activity; (3) no concurrent GLP-1 or GLP-1/GIP agonist; (4) continued history of use or contraindication to GDMT (antiplatelet, statin, blood pressure medication). BMI threshold and age are NOT re-verified at renewal.
How current is this information?: The oldest review date among the policies on this page is June 5, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Summary of Kaiser Permanente Southern California's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.